The following pages link to Peter F. Thall (Q395985):
Displayed 50 items.
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs (Q70261) (← links)
- A modified adaptive Lasso for identifying interactions in the Cox model with the heredity constraint (Q395986) (← links)
- A theorem on regular infinitely divisible Cox processes (Q595269) (← links)
- A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity (Q665054) (← links)
- Bayesian models and decision algorithms for complex early phase clinical trials (Q903294) (← links)
- A review of phase 2-3 clinical trial designs (Q1029784) (← links)
- On the structure of regular infinitely divisible point processes (Q1240969) (← links)
- Random measures with aftereffects (Q1244935) (← links)
- Bayesian variable selection for a semi-competing risks model with three hazard functions (Q1654272) (← links)
- A decision-theoretic comparison of treatments to resolve air leaks after lung surgery based on nonparametric modeling (Q1699679) (← links)
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes (Q2057378) (← links)
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials (Q2080762) (← links)
- Bayesian semiparametric joint regression analysis of recurrent adverse events and survival in esophageal cancer patients (Q2415456) (← links)
- Some geometric methods for constructing decision criteria based on two-dimensional parame\-ters (Q2475737) (← links)
- Prior effective sample size in conditionally independent hierarchical models (Q2633927) (← links)
- (Q2829294) (← links)
- Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes (Q2861956) (← links)
- Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion (Q2893431) (← links)
- Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials (Q3078842) (← links)
- Decision-Theoretic Designs for Pre-Phase II Screening Trials in Oncology (Q3078865) (← links)
- Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials (Q3078908) (← links)
- Adaptive Decision Making in a Lymphocyte Infusion Trial (Q3078989) (← links)
- Seamlessly Expanding a Randomized Phase II Trial to Phase III (Q3079028) (← links)
- Dose-Finding with Two Agents in Phase I Oncology Trials (Q3079137) (← links)
- Some Covariance Models for Longitudinal Count Data with Overdispersion (Q3197135) (← links)
- Distribution-Free Confidence Intervals for a Parameter of Wilcoxon-Mann- Whitney Type for Ordered Categories and Progressive Censoring (Q3201346) (← links)
- A Two-Stage Design for Choosing among Several Experimental Treatments and a Control in Clinical Trials (Q3201542) (← links)
- A joint characterization of the multinomial distribution and the Poisson process (Q3308792) (← links)
- Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcome (Q3465746) (← links)
- Mixed Poisson Likelihood Regression Models for Longitudinal Interval Count Data (Q3489272) (← links)
- Determining the Effective Sample Size of a Parametric Prior (Q3506509) (← links)
- Monitoring late-onset toxicities in phase I trials using predicted risks (Q3526173) (← links)
- Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates (Q3549405) (← links)
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials (Q3576931) (← links)
- Two-stage selection and testing designs for comparative clinical trials (Q3780331) (← links)
- Cluster shock models (Q3896325) (← links)
- Huber-Sense Robust M-Estimation of a Scale Parameter, with Applications to the Exponential Distribution (Q4185654) (← links)
- Count distributions, orderliness and invariance of Poisson cluster processes (Q4188523) (← links)
- (Q4191947) (← links)
- Score tests in the two - way layout of counts (Q4202702) (← links)
- Semiparametric Regression Analysis for Recurrent Event Interval Counts (Q4381025) (← links)
- Estimating Genomic Category Probabilities from Fluorescent in Situ Hybridization Counts with Misclassification (Q4390925) (← links)
- Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials (Q4468361) (← links)
- A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes (Q4559706) (← links)
- Clinical trial design as a decision problem (Q4620208) (← links)
- A utility‐based design for randomized comparative trials with ordinal outcomes and prognostic subgroups (Q4628384) (← links)
- (Q4642533) (← links)
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials (Q4665957) (← links)
- Treatment Comparisons Based on Two‐Dimensional Safety and Efficacy Alternatives in Oncology Trials (Q4666639) (← links)
- Decision Theoretic Designs for Phase II Clinical Trials with Multiple Outcomes (Q4666685) (← links)